1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Summit Therapeutics agreed on September 28, 2026 to sell 108,955.3686 shares of Class A Convertible Preferred Stock to AstraZeneca Holdings B.V. for $2.0 billion in gross proceeds, and also signed a separate clinical trial collaboration with AstraZeneca on sonesitatug vedotin combined with ivonescimab. Shareholders would face dilution once the preferred converts into common stock, which is subject to conditions and a registration statement, and the company must redeem the preferred for cash if a required share authorization is not effective within 18 months.
Purchase price of $18,356.14 per preferred share, based on a common stock price of $18.3561; each preferred share converts into 1,000 common shares
Closing is expected within five business days of the Purchase Agreement, subject to customary conditions
Conversion is barred until the later of any Hart-Scott-Rodino waiting period expiration and effectiveness of the authorized share increase charter amendment
Company must file a resale registration statement within 60 days after closing; cash redemption required if the share increase is not effective within 18 months
Futurewave Acquisition Corp (FWAC), a Nasdaq-listed special purpose acquisition company, signed a merger agreement with Olympian Group Inc., a Cayman Islands holding company of Hong Kong-based HK Shang Ge Industrial Limited, which provides integrated chip and electronic component solutions. Olympian shareholders would receive 40,000,000 Purchaser ordinary shares valued at $10.00 per share, based on a Company Net Value of $400,000,000, and the combined company is expected to be Nasdaq-listed, subject to shareholder and regulatory approvals. The deal is not yet completed and the filing sets a closing deadline of June 26, 2027, unless extended.
Olympian shareholders to receive 40,000,000 Purchaser ordinary shares valued at $10.00 each, based on a $400,000,000 Company Net Value
Board of the combined company to have five directors, one appointed by Futurewave and four by Olympian
Either party may terminate if closing has not occurred by June 26, 2027, subject to extension and exceptions
Closing requires Futurewave and Olympian shareholder approvals, an effective Form F-4 registration statement, and HSR or other antitrust clearance
At its 2026 Annual Meeting on September 24, 2026, Korn Ferry stockholders elected all nine director nominees, approved an advisory resolution on executive pay, approved the amended and restated 2022 Stock Incentive Plan, and ratified Ernst & Young LLP as auditor for fiscal 2027. The amended plan adds 1,400,000 shares for stock-based awards and extends its term to September 24, 2036, which sets the terms under which future equity may be granted to employees and directors.
Plan adds 1,400,000 shares available for stock-based awards and extends term to September 24, 2036
Plan approved with 43,102,365 votes for and 2,155,490 against
Executive compensation advisory resolution approved with 43,800,129 votes for and 1,145,915 against
Ernst & Young LLP ratified as independent auditor for fiscal 2027 with 46,296,359 votes for
On September 28, 2026, AAR agreed to acquire a 65% controlling interest in MRO Holdings, an aircraft maintenance provider, for an estimated cash price of $1,819,174,310 plus Series A preferred stock with an agreed value of $780,825,690, subject to adjustments and closing conditions including regulatory approvals. The deal is expected to close in AAR's fiscal third quarter ending February 2027 and is to be funded partly by about $2.1 billion of new debt, which AAR expects to take net leverage to about 3.6x at closing. The filing also notes that a private investment in public equity offering may dilute existing stockholders, and the company's fiscal 2026 adjusted EBITDA was $401.1 million, up from $324.2 million.
Estimated cash purchase price of $1,819,174,310 and Series A preferred stock with an agreed value of $780,825,690, plus a $22,500,000 escrow deposit
Implied enterprise value of $4.0 billion; AAR expects about $2.1 billion of new debt financing and net leverage of about 3.6x at closing
Expected close in fiscal third quarter ending February 2027, subject to regulatory approvals; termination fee of $100,000,000 ($150,000,000 if the outside date is extended) applies if competition approvals fail
Press release shows fiscal 2026 net income of $187.7 million versus $12.5 million in fiscal 2025, and adjusted EBITDA of $401.1 million versus $324.2 million
NETSOL reported record full-year fiscal 2026 revenue of $74.4 million, up 12.5% and above its $73 million guidance, and operating income nearly doubled to $6.9 million. GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, roughly flat with the prior year's $0.25, as a foreign exchange swing and higher non-controlling interest offset operating gains. The company also issued fiscal 2027 guidance calling for revenue growth of 13% to 16%.
Fourth-quarter fiscal 2026 revenue rose 12.5% to a record $20.7 million, and operating income rose 40.2% to $4.5 million.
Full-year GAAP net income attributable to NETSOL was $2.95 million, or $0.25 per diluted share, compared with $2.9 million, or $0.25, a year earlier.
Fiscal 2027 guidance: revenue growth of 13% to 16%, gross margin of approximately 50% or better, and adjusted EBITDA growth of 15% to 25%.
Cash was $27.1 million at June 30, 2026, and operating cash flow was $13.9 million versus $0.4 million a year earlier.
National Healthcare Properties said that on September 25, 2026, the purchaser's termination rights under a July 15, 2026 agreement to sell its 40 outpatient medical facilities for approximately $531 million ended. The company expects the sale to close in the fourth quarter of 2026, subject to customary closing conditions. For shareholders, the filing confirms the pending sale is moving toward closing but does not describe its effect on earnings or future results.
Sale of 40 outpatient medical facilities for approximately $531 million, before transaction expenses, prorations and adjustments
Purchaser's termination rights terminated on September 25, 2026, under the purchase and sale agreement dated July 15, 2026
Closing expected in the fourth quarter of 2026, subject to customary closing conditions
Full agreement to be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2026, with some portions possibly omitted
Clearway Energy subsidiary Swan Purchaser LLC agreed on September 23, 2026 to buy membership interests in Swan TargetCo LLC from an affiliate of Clearway Energy Group for a base price of about $230 million in cash, subject to adjustments. Swan TargetCo will indirectly own Swan Solar, which is developing a 650-megawatt solar facility in Bates County, Missouri, and the deal is expected to close in the third quarter of 2028 subject to conditions.
Base purchase price of approximately $230 million in cash, subject to adjustments tied to a financial model with minimum economic thresholds
Swan Solar is developing and constructing a solar photovoltaic facility with about 650 megawatts of installed capacity in Bates County, Missouri
Closing expected during the third quarter of 2028, subject to customary conditions and third-party actions
Seller is Swan CE Seller LLC, an affiliate of Clearway Energy Group LLC; Purchaser will hold 100% of Target Company class A units at closing
Surf Air Mobility appointed Jason Secore as Chief Financial Officer effective September 30, 2026, succeeding Oliver Reeves, who is stepping down to pursue other opportunities. Reeves will continue to support the company as an advisor. The filing also includes Secore's employment agreement, dated September 24, 2026.
Jason Secore becomes CFO effective September 30, 2026, succeeding Oliver Reeves.
Secore has 18 years of finance leadership experience, most recently as CFO of Matternet.
Oliver Reeves is stepping down to pursue other opportunities and will continue as an advisor.
Employment agreement dated September 24, 2026, effective September 30, 2026, is filed as Exhibit 10.1.
Viking Therapeutics sold 7,857,143 shares of common stock at $35.00 per share and separately sold $225.0 million of 2.00% convertible senior notes due 2032, with underwriters exercising their options in full. Net proceeds were about $297.0 million from the stock sale and about $250.8 million from the notes, which the company intends to use for its VK2735 and VK3019 programs and general corporate purposes. The stock sale adds shares outstanding for existing shareholders, and the notes add debt that could convert into common stock at about $50.75 per share.
Stock: 7,857,143 shares at $35.00 per share, plus 1,178,571 option shares exercised in full on September 24, 2026; closed September 25, 2026; net proceeds about $297.0 million
Notes: $225.0 million of 2.00% convertible senior notes due October 15, 2032, plus a $33,750,000 option exercised in full on September 24, 2026; net proceeds about $250.8 million
Conversion price about $50.75 per share (19.7044 shares per $1,000 principal); company may settle conversions in cash, shares or a combination
Proceeds intended for VK2735 and VK3019 clinical programs and general corporate purposes
Sabre Financial Borrower, a Sabre subsidiary, issued $1.35 billion of 9.875% senior secured notes maturing October 15, 2032, and used the proceeds to refinance part of Sabre GLBL's debt and repurchase portions of its 10.750% and 11.125% notes due 2029 through tender offers. The filing also reports early tender results showing more than 90% of a separate 11.125% note series tendered, which the company plans to redeem, so the refinancing reshapes Sabre's debt structure and secured creditor position.
SPV Notes: $1.35 billion principal, 9.875% annual interest, payable April 15 and October 15, maturing October 15, 2032
Sabre GLBL accepted about $251.9 million of 10.750% 2029 notes at $992.50 per $1,000 principal, with proration of about 84.0%
Early tender results: $930.7 million, or 93.07%, of the 11.125% 2029 notes tendered by September 25, 2026; redemption expected October 13, 2026
Settlement of the tender offers is expected September 28, 2026
AST SpaceMobile's Compensation Committee adopted a Senior Management Change of Control Severance Policy on September 25, 2026, covering the CEO, President, and all Executive and Senior Vice Presidents. The policy sets cash severance, benefit continuation, and equity vesting terms that apply if an executive is terminated without cause or resigns for constructive discharge around a change of control.
Adopted September 25, 2026; applies to the CEO, the President, and all EVPs and SVPs, including all named executive officers
CEO payment multiple is 2.0 times base salary plus target bonus; other eligible employees receive 1.5 times
Benefit continuation runs 24 months for the CEO and 18 months for other eligible employees; performance awards convert to time-based awards on a change of control
Nexalin Technology received a Nasdaq Hearings Panel decision allowing its common stock to stay listed on The Nasdaq Capital Market, subject to conditions. The company must meet the $1.00 minimum bid price by September 28, 2026 and the $2,500,000 stockholders' equity requirement by January 4, 2027, or its stock faces delisting.
Panel granted continued listing in a notice received September 25, 2026.
Company must show a closing bid price of $1.00 or greater for at least 20 consecutive trading sessions.
Stockholders' equity must meet the $2,500,000 minimum by January 4, 2027.
Filing states there can be no assurance the company will meet the conditions.
Exascale Labs reported fiscal 2026 revenue of $14.8 million, up 111% from $7.0 million, but its net loss widened to $12.2 million from $7.7 million. The loss increase reflects higher operating expenses and a $7.4 million non-cash fair value change on simple agreements for future equity (SAFEs), which converted into Class A common stock when the Nasdaq business combination closed on August 27, 2026, eliminating a $29.1 million liability.
Revenue was $14.8 million versus $7.0 million; revenue from the intelligent computing power service rose 124.0%.
Net loss was $12.2 million versus $7.7 million, including a $7.4 million change in fair value of SAFEs.
Operating expenses rose to $7.2 million from $4.2 million; gross margin was 16.3% versus 15.8%.
Business combination closed August 27, 2026, with approximately $11.8 million in net cash proceeds; shares began trading on Nasdaq as XLAB on August 28, 2026.
U.S. Physical Therapy entered a 45-month forward-starting interest rate swap with Bank of America on September 22, 2026, with an initial notional amount of $170.6 million. The swap fixes the variable interest rate on the term debt under its April 14, 2026 credit agreement, starting June 30, 2027, when its existing swap expires. The filing describes this as a hedge on borrowing costs, with no earnings figures disclosed.
Swap notional amount: $170.6 million, reflecting term loan amortization as of the effective date
Company pays a fixed rate of 4.578% per annum and receives one-month SOFR; swap effective June 30, 2027
Swap terminates April 14, 2031; Bank of America is counterparty and Administrative Agent under the credit agreement
The Trustee issued a release answering Unit Holder questions about administrative expenses, a 2017–2020 joint interest audit adjustment, Hilcorp capital spending, and liquidity. It states general and administrative expenses fell by about $976,000 year over year, mainly due to costs from the 2024 trustee transition that did not recur, and that the $2,000,000 Texas Bank credit facility, maturing May 21, 2027, is being discussed for extension, renewal, or replacement.
General and administrative expenses decreased by approximately $976,000 year over year, mainly from non-recurring 2024 trustee transition costs
Outstanding principal on the $2,000,000 Texas Bank Line of Credit was approximately $1,075,400 as of September 18, 2026; the facility matures May 21, 2027
The Trustee is in talks with Texas Bank and evaluating other financing sources, including other commercial lenders, Unit Holders, and private lenders
National newswire distribution of monthly press releases will be restored, beginning with the October 2026 release
AAR CORP. reported first-quarter fiscal 2027 results for the period ended August 31, 2026, with sales up 24% to $918.0 million and GAAP diluted EPS of $1.00, compared with $0.95 a year earlier. The company also announced a definitive agreement to acquire a 65% controlling interest in MRO Holdings, and the guidance it gave excludes that acquisition's effect, so shareholders face both the quarterly gains and a large pending deal.
Q1 sales of $918.0 million, up 24% from $739.6 million; GAAP net income of $40.1 million versus $34.4 million
Adjusted diluted EPS of $1.49, up from $1.08; adjusted EBITDA of $116.5 million, up 34%
Full-year fiscal 2027 sales growth guidance (ex. LCP) changed to low teens from low double-digits to low teens; second-quarter sales growth guidance set at 14% to 16%
Net debt of $780.5 million and net leverage of 1.81x at August 31, 2026; acquisition expenses rose to $19.6 million from $4.4 million
PCB Bancorp, the holding company for PCB Bank, said its Board approved on September 23, 2026 a share repurchase program for up to 700,000 shares of common stock, authorized through September 22, 2027. The filing says the company may buy shares in the open market, in block purchases, or in privately negotiated deals, and that it intends to use a Rule 10b5-1 trading plan administered by an independent broker.
Board approved the program on September 23, 2026, for up to 700,000 shares of common stock
Program is authorized through September 22, 2027 and may be modified, discontinued, or suspended at any time
Company is not obligated to buy any specific number of shares; timing and price are at its discretion
Company intends to use a Rule 10b5-1 trading plan administered by an independent broker, subject to price, volume and timing restrictions
Viking Acquisition Corp. I, a special purpose acquisition company, said it expects to complete its business combination with NorthStar Earth & Space Inc. on September 30, 2026. The combined company is expected to begin trading as NorthStar Earth & Space Enterprises, Inc. on NYSE American on October 1, 2026, which matters to shareholders because it changes the company's listing venue and ticker.
Expected closing of the business combination: Wednesday, September 30, 2026, subject to customary closing conditions
Expected first day of trading on NYSE American: Thursday, October 1, 2026, under NSTR for common shares and NSTR.WS for public warrants
Viking will transfer its listing from the New York Stock Exchange to NYSE American in connection with the closing
StandardAero announced that Chief Operating Officer Kimberly Ernzen will no longer serve in that role as of September 28, 2026. She will stay employed through December 31, 2026 to support the leadership transition, and the company expects to enter into a transition agreement with her, terms not yet determined.
Kimberly Ernzen ceases to be Chief Operating Officer effective September 28, 2026
Ernzen remains employed and supports the leadership transition through December 31, 2026
Transition agreement terms have not yet been determined by the company
At an Analyst Day on September 28, 2026, CAMP4 Therapeutics described the design and timing of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder and gave a pipeline update. The company expects to dose the first patient by the end of 2026 and targets topline data in the first half of 2028, so the update sets out timelines but reports no clinical results or financial figures.
The company expects to dose the first patient in the ASCEND trial by the end of 2026 and targets topline data in the first half of 2028.
The trial plans three multiple ascending dose cohorts with a minimum of eight participants each, randomized 3:1 to intrathecal CMP-002 or a sham procedure.
The company expects to designate a development candidate in its SHANK3 program for Phelan-McDermid Syndrome in 2027, citing more than 45,000 US patients.
Greenland Mines Ltd. agreed on September 28, 2026 to sell 1,320,000 shares of common stock in a direct registered offering to institutional investors, with expected net proceeds of about $17.2 million. The offering is expected to close on or about September 29, 2026, and the company plans to use the proceeds with existing cash for its Greenland mining operations and general working capital, which would add new shares outstanding and dilute existing holders.
1,320,000 shares of common stock offered; expected net proceeds of about $17.2 million after offering expenses
Expected closing on or about September 29, 2026, subject to customary closing conditions
On September 23, 2026, the company terminated its August 24, 2026 at-the-market sales agreement with A.G.P./Alliance Global Partners, under which $1,388,827.04 of shares had been sold
IDT reported fiscal fourth-quarter 2026 revenue of $339.0 million, up 7%, and income from operations of $33.2 million, up 52%. For the full fiscal year, revenue rose 5% to $1,298.0 million and GAAP diluted EPS increased to $3.46 from $3.01. The company guided fiscal 2027 Adjusted EBITDA to $176 million to $180 million, while full-year operating cash flow fell to $91.1 million from $127.1 million.
Q4 2026 revenue rose 7% to $339.0 million; income from operations rose 52% to $33.2 million
FY 2026 revenue rose 5% to $1,298.0 million; income from operations rose 21% to $121.2 million
FY 2026 GAAP diluted EPS was $3.46, up from $3.01 in FY 2025
FY 2027 outlook: Adjusted EBITDA of $176 million to $180 million; FY 2026 net cash from operations fell to $91.1 million from $127.1 million
Unicycive Therapeutics disclosed that a securities class action was filed on September 3, 2026, in the U.S. District Court for the Northern District of California against the company and certain officers. The suit alleges violations of federal securities laws tied to public statements about the company's new drug application for oxylanthanum carbonate phosphate binder. The company says the claims are meritless and plans to defend the lawsuit vigorously, but the filing does not state any financial impact.
Class action filed September 3, 2026, in U.S. District Court for the Northern District of California
Suit names the company and certain officers and alleges federal securities law violations
Allegations relate to public statements about the new drug application for oxylanthanum carbonate phosphate binder for hyperphosphatemia in dialysis patients with chronic kidney disease
Company says the claims are meritless and intends to vigorously defend
Gain Therapeutics said its senior vice president of finance and principal financial officer, Gianluca Fuggetta, will resign effective September 30, 2026, to pursue other opportunities. The board appointed CEO Gene Mack as interim chief financial officer effective October 1, 2026, and the company is searching for a permanent replacement.
Gianluca Fuggetta gave notice on September 22, 2026; resignation effective September 30, 2026
Gene Mack, current President and CEO, appointed interim CFO effective October 1, 2026
Mack also assumes principal financial and principal accounting officer duties; his employment terms are unchanged
Company is conducting an ongoing search for a permanent principal financial officer
Wintergreen Acquisition Corp. issued a $184,635 non-interest-bearing promissory note to its sponsor, MACRO DREAM Holdings Limited, to fund a deposit into its trust account for an extension. The board approved extending the deadline for completing its business combination with KIKA Technology Inc. from September 30, 2026 to October 30, 2026, and the company says it continues to pursue that deal.
Note principal of $184,635 issued September 28, 2026 to sponsor MACRO DREAM Holdings Limited
Business combination deadline extended from September 30, 2026 to October 30, 2026
Sponsor may convert unpaid note principal into units at $10.00 per unit upon a business combination
Note is forgiven and the sponsor waives trust account claims if no business combination is completed
Precision Optics reported fiscal 2026 revenue of $31.5 million, up about 65%, and a narrower net loss of $3.6 million, or $0.43 per share, compared with $5.8 million, or $0.85 per share, a year earlier. The company guided fiscal 2027 revenue to $30 million to $33 million, similar to fiscal 2026, citing a pause in orders from an existing satellite customer that it expects to partly offset with other programs and a stronger second half. For shareholders, the results show strong growth and smaller losses, but the outlook projects no revenue growth for the coming year.
Fourth quarter ended June 30, 2026: revenue of $8.8 million, up about 42% from $6.2 million a year earlier, with a net loss of $0.1 million versus $1.4 million.
Fiscal 2026 revenue of $31.5 million, up about 65% from $19.1 million; net loss of $3.6 million, or $0.43 per share, versus $5.8 million, or $0.85 per share.
Fiscal 2027 revenue guidance of $30 million to $33 million, similar to fiscal 2026, reflecting a pause in orders from an existing satellite customer.
Fiscal 2027 Adjusted EBITDA guidance of $(1.2) million to $(1.7) million loss, compared with a $(2.1) million loss in fiscal 2026.
Teledyne said Vice Chairman Jason VanWees will retire effective February 1, 2027. Mary Grace DeForest, Senior Vice President and General Manager of Teledyne Microwave, will become Corporate Vice President of Investor Relations and Mergers and Acquisitions effective November 1, 2026. VanWees has led the identification and acquisition of 75 businesses for cumulative consideration of $12.8 billion, so the change affects the company's acquisition and investor communication roles.
Jason VanWees, Vice Chairman, retires effective February 1, 2027, at age 55
Mary Grace DeForest appointed Corporate Vice President of Investor Relations and M&A, effective November 1, 2026
DeForest is SVP and General Manager of Teledyne Microwave, with 880 employees and annual revenue of $320 million
VanWees led acquisitions of 75 businesses for cumulative consideration of $12.8 billion
PetMed Express increased the share reserve under its 2024 Inducement Incentive Plan by 500,000 shares, bringing the total to 850,000, effective September 27, 2026. The increase covers equity grants promised to Jeffrey Allen Willard, the new Chief Executive Officer, whose start date is September 28, 2026, so the change adds potential dilution for shareholders.
Share reserve under the Inducement Incentive Plan rises by 500,000 shares to 850,000 total.
The increase matches 250,000 restricted stock shares plus 250,000 performance share units promised to CEO Jeffrey Allen Willard.
Willard's start date is September 28, 2026; the plan was amended and restated as of September 27, 2026.
No other changes were made to the original plan, per the filing.
Ready Capital Corporation said its subsidiary ReadyCap Holdings II closed a private placement of $225.0 million of 10.00% senior secured notes due 2031 on September 28, 2026. On the same day, an indirect subsidiary redeemed the entire $350.0 million of its 4.50% senior secured notes due 2026 at 100% of principal plus accrued interest. The filing is a financing refinancing update and does not report revenue, earnings or guidance.
New Notes: $225.0 million aggregate principal, 10.00% coupon, due 2031, closed September 28, 2026
Existing Notes: entire $350.0 million 4.50% senior secured notes due 2026 redeemed September 28, 2026
Redemption price: 100% of principal amount plus accrued and unpaid interest
Offering was previously priced and disclosed in a Form 8-K filed September 18, 2026
Neurocrine Biosciences appointed Eiry W. Roberts, M.D., as Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D., whose service ended September 25, 2026 by mutual agreement. The filing says Dr. Roberts will receive a base salary of $825,000, a target bonus of 60% of base pay, and about $1.25 million in target equity grants, and that Dr. Keswani will receive severance under the company's Executive Severance Plan.
Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
Dr. Roberts was appointed Chief Medical Officer effective September 28, 2026, with an annual base salary of $825,000 and a target bonus of 60% of base pay for 2026.
Target equity grants total about $1.25 million: stock options of about $625,000, restricted stock units of about $250,000, and performance-vesting restricted stock units of about $375,000.
The final Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.
Jefferies reported results for the quarter ended August 31, 2026, with net earnings attributable to common shareholders of $261 million, up from $224 million a year earlier, and total net revenues of $2.22 billion, up from $2.05 billion. Investment Banking and Equities reached record quarterly revenue, while Fixed Income and Asset Management declined. The board also raised the share buyback authorization to $250 million and declared a $0.40 quarterly dividend.
Total net revenues of $2.22 billion versus $2.05 billion in the prior year quarter.
Diluted earnings per voting common share of $1.08 versus $1.01; return on adjusted tangible shareholders' equity of 13.5% versus 13.6%.
Asset management fees and investment return of $34 million versus $84 million in the prior year quarter.
Quarterly dividend of $0.40 payable November 25, 2026; buyback authorization increased to $250 million.
Asana's board appointed CEO Dan Rogers as Board Chair effective September 25, 2026, succeeding Dustin Moskovitz, who remains a director. The board also expanded from seven to nine members with Tom Berquist and Jerry Ting, and named Heather Le as Chief Accounting Officer and Principal Accounting Officer. The filing describes these as governance and leadership changes and does not report any financial results.
Dan Rogers, CEO and a Class III director, was appointed Board Chair effective September 25, 2026, and is not eligible for director compensation as an employee.
Tom Berquist (Class II, term to the 2028 annual meeting) and Jerry Ting (Class I, term to the 2027 annual meeting) were appointed directors, increasing the board from seven to nine members.
Heather Le was appointed Chief Accounting Officer with a $400,000 annual base salary, a 15% initial target bonus and a $1,000,000 target-value RSU grant subject to Compensation Committee approval.
Hain Celestial's common stock was transferred from The Nasdaq Global Select Market to The Nasdaq Capital Market on September 24, 2026, and Nasdaq granted an additional 180-day period, to March 22, 2027, to regain the $1.00 minimum bid price. The company may need a reverse stock split, and it states there is no assurance it will regain or maintain compliance. Separately, Chief Accounting Officer Michael J. Ragusa plans to resign effective November 1, 2026, and CFO Lee A. Boyce will also take on the principal accounting officer role.
Stock transferred to The Nasdaq Capital Market at the opening of business on September 24, 2026, and continues to trade as HAIN
Nasdaq deficiency: closing bid price below $1.00 for 30 consecutive business days; second compliance period ends March 22, 2027
Compliance requires closing at or above $1.00 for at least ten consecutive business days; a reverse stock split may be used if necessary
Michael J. Ragusa resigns as SVP, Chief Accounting Officer, effective November 1, 2026; Lee A. Boyce takes on the principal accounting officer role
Workhorse Group's board adopted a Value Creation Incentive Plan on September 22, 2026, and granted performance awards to CEO Scott Griffith ($15 million target) and CFO Jody Davis ($6.5 million target). Payouts depend on revenue, gross margin, operating cash flow and market capitalization milestones over a performance period from October 1, 2026 to September 30, 2031.
CEO Scott Griffith target award is $15 million; CFO Jody Davis target award is $6.5 million.
Performance period runs from October 1, 2026 to September 30, 2031.
Equity value milestone (40% of target) requires a $500 million average market capitalization over any 45-trading-day period.
Awards may be paid in cash or, at the Committee's election, in common stock.
OPENLANE's subsidiaries amended two receivables purchase facilities on September 25, 2026, extending the termination date of each from January 31, 2028 to January 31, 2030. The filing describes the extension as a term extension and does not mention new borrowing capacity, pricing changes, or costs.
U.S. facility: Second Amendment to the Tenth Amended and Restated Receivables Purchase Agreement, signed September 25, 2026, extends termination date to January 31, 2030
Canadian facility: Amendment No. 4 to the Receivables Purchase Agreement dated March 1, 2023, signed September 25, 2026, extends termination date to January 31, 2030
Full amendment texts will be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026
Voyager Technologies issued $402.5 million of 0% convertible senior notes due October 15, 2032, on September 28, 2026, including $52.5 million from the initial purchasers' full option exercise. The company reported net proceeds of approximately $391.6 million and plans to use about $52.5 million to fund capped call transactions, with the rest for general corporate purposes. Holders can convert into cash, Class A common stock, or a mix, which could dilute existing shareholders if the notes are converted into shares.
Principal: $402.5 million, including $52.5 million from the full exercise of the initial purchasers' option
Initial conversion price of approximately $40.82 per share, a premium of about 30% over the $31.40 close on September 23, 2026
Capped calls have a cap price of $78.50 per share and cost approximately $52.5 million
Net proceeds of approximately $391.6 million; the notes mature October 15, 2032
Vail Resorts reported fiscal 2026 results for the year ended July 31, 2026, with net income attributable to the company falling to $147.5 million from $280.0 million, which it attributed mainly to weather. The company also gave fiscal 2027 guidance of $158 million to $233 million in net income and $805 million to $865 million in Resort Reported EBITDA, and said season pass unit sales were down about 12% through September 18, 2026.
Fiscal 2026 net income attributable to Vail Resorts was $147.5 million, versus $280.0 million a year earlier; Resort Reported EBITDA was $745.7 million, versus $844.1 million.
Fourth-quarter net loss attributable to Vail Resorts was $190.2 million, compared with a $182.4 million loss in the prior-year quarter.
Fiscal 2027 guidance: net income attributable to Vail Resorts of $158 million to $233 million and Resort Reported EBITDA of $805 million to $865 million.
Pass product units sold through September 18, 2026 fell about 12%, and sales dollars fell about 6%; the quarterly dividend is $2.22 per share, payable October 27, 2026.
Adeia Inc. said Dipti Vachani, a former Arm Limited executive, will become chief executive officer and a board member effective October 12, 2026, succeeding Paul E. Davis, who is leaving to focus on his health and personal pursuits. The filing sets out her pay package, including a $730,000 base salary and an $11,000,000 target equity grant, along with severance terms and a consulting arrangement for Davis.
Vachani's CEO start date and board seat are both effective October 12, 2026; Davis's consulting agreement runs through December 31, 2026.
Vachani's offer letter provides a $730,000 base salary and a target bonus of 100% of base salary.
Target equity grants total $11,000,000, including a $4,400,000 time-based RSU award and a $6,600,000 performance-based RSU award.
Davis will receive a fixed consulting fee of $183,000.
On September 16, 2026, IQSTEL amended its 2025 agreement to acquire 51% of GlobeTopper, LLC, replacing a $500,000 payment originally due in restricted common stock with $500,000 in cash. The company must pay $80,000 within five business days, then $70,000 on the first business day of each of six following months, and the payments are secured by its GlobeTopper interest. If the company fails to cure a missed payment, the seller could seek to rescind the deal and take back the 51% interest, which would end the related earn-out obligations.
September 16, 2026: amendment replaces $500,000 in buyer shares with a $500,000 cash payment; the company has no further obligation to issue those shares
Payment schedule: $80,000 within five business days, then $70,000 on the first business day of each of six consecutive months
Missed payments not cured within 30 days after notice are an Event of Default; the seller may accelerate, foreclose on the collateral, or rescind and reclaim the 51% GlobeTopper interest
Par Pacific appointed Jerry Stumbo, formerly a Valero refinery general manager, as Executive Vice President of Refining and Logistics effective September 28, 2026. Richard Creamer, the current executive in the role, will serve as Senior Advisor until his planned retirement on or about April 1, 2027.
Jerry Stumbo, age 55, joins from Valero Energy, where he was VP and General Manager of the Port Arthur, Texas Refinery
Stumbo's Port Arthur refinery has approximately 435,000 barrels per day of throughput capacity
Richard Creamer retires effective on or about April 1, 2027, after serving as Senior Advisor from September 28, 2026
ADARx Pharmaceuticals closed its initial public offering on September 28, 2026, selling 26,250,000 shares at $17.00 each for approximately $446.3 million in gross proceeds. AbbVie bought 5,255,542 shares in a concurrent private placement for approximately $89.3 million in gross proceeds, leaving it with about 4.9% of outstanding common stock after the closings. The company also adopted an amended and restated certificate of incorporation and bylaws in connection with the IPO.
IPO closed September 28, 2026: 26,250,000 shares at $17.00 per share, approximately $446.3 million in gross proceeds.
AbbVie bought 5,255,542 shares in a private placement at the IPO price, approximately $89.3 million in gross proceeds, owning about 4.9% after closing.
Placement agent fee was 2.0% of the private placement purchase price; J.P. Morgan, Morgan Stanley, TD Securities, UBS and LifeSci Capital acted as agents.
Amended and restated certificate of incorporation and bylaws took effect September 28, 2026.
SCYNEXIS entered a contract with the U.S. Biomedical Advanced Research and Development Authority to develop its SCY-247 antifungal candidate, with potential non-dilutive funding of up to $214 million if all options are exercised. The initial base period provides approximately $18.5 million to advance SCY-247 into a Phase 2 study in patients with invasive candidiasis. The company says its SCY-770 development plans and cash runway into 2029 are unchanged.
Contract signed September 25, 2026; base period starts September 2026 with approximately $18.5 million
Potential total funding up to $214 million; BARDA may exercise up to six options extending the term up to ten years
Cost-share arrangement; company expects to fund its share of near-term SCY-247 costs within its existing operating plan
Full contract to be filed as an exhibit to the Form 10-Q for the quarter ending September 30, 2026, with confidential terms redacted
Archrock's Vice President and Chief Accounting Officer, Donna A. Henderson, notified the company on September 23, 2026 that she intends to retire effective December 4, 2026. The filing does not name a successor or describe any financial impact, so the change's effect on shareholders is not yet clear.
Donna A. Henderson, Vice President and Chief Accounting Officer, plans to retire.
Notice was given to the company on September 23, 2026.
The Marygold Companies agreed on September 25, 2026 to be acquired by funds managed by Madison Dearborn Partners, with stockholders to receive $2.00 per share in cash, a premium of approximately 100% over the September 24, 2026 closing price. Stockholders holding about 75% of the voting power have already approved the merger by written consent, and the company's common stock will be delisted from NYSE American once the deal closes, which is expected in the first half of 2027 or earlier.
Stockholders will receive $2.00 per share in cash, a premium of approximately 100% over the September 24, 2026 closing price.
Written stockholder consent from holders of about 75% of voting power was delivered on September 25, 2026, satisfying the stockholder approval condition.
Common stock will stop trading on NYSE American after closing; the company will become privately held.
A termination fee of approximately $2.6 million may be payable by the company in certain circumstances; the Termination Date is June 7, 2027.
CapsoVision said the U.S. Food and Drug Administration cleared AI Highlights, an AI-assisted reading feature for its CapsoCam Plus capsule endoscopy system, on September 25, 2026. The company announced the clearance on September 28, 2026, and the filing contains no revenue, profit, or guidance figures, so its direct financial effect on shareholders is not quantified.
FDA clearance received September 25, 2026; announced September 28, 2026
Tool flags suspected abnormal lesions in small bowel capsule studies to reduce physician review time
Intended for adult and pediatric patients over two years old with suspected small bowel bleeding; does not replace gastroenterologists' diagnosis
Core Molding Technologies furnished slides from its September 28, 2026 investor day under Item 7.01, with the presentation attached as Exhibit 99.1 and posted on its website. The slides show trailing-twelve-month revenue fell from $377 million in 2022 to $254 million through the second quarter of 2026, while the company says its adjusted EBITDA margin improved from 8.7% in 2025 to 11.2%, which it presents as the result of its operating turnaround.
Trailing-twelve-month revenue of $254 million through Q2 2026, versus $274 million in 2025 and $377 million in 2022 per the slides
Adjusted EBITDA margin improved from 8.7% in 2025 to 11.2% per the slides; adjusted EBITDA is a non-GAAP measure
Slides cite $89 million of incremental annual revenue from new wins over 18 months and $210 million of annual revenue in active quotes
CEO Eric Palomaki and CFO Alex Panda are among presenters; the company says it aims to reach $500 million in revenue through economies of scale
Proem Acquisition Corp I (Nasdaq: PAAC), a blank check company, entered a merger agreement dated September 26, 2026 with Astro Digital US, Inc., an aerospace company that provides modular satellite technology infrastructure and mission support services. The deal would move Proem from the Cayman Islands to Delaware and combine it with Astro Digital, with Proem shareholders asked to approve it and closing anticipated in the first quarter of 2027. For shareholders, the outcome depends on the shareholder vote, the minimum cash condition, and how many shares are redeemed.
Merger agreement dated September 26, 2026 with Astro Digital US, Inc.; Proem would domesticate to Delaware and be renamed, with a name to be mutually agreed.
Base purchase price of $525,000,000 plus the aggregate exercise price, paid in Parent common shares valued at $10.00 each.
Parent to use 20% of the gross proceeds of the PIPE investment to repurchase shares from selling Astro Digital stockholders at $10.00 per share after the Second Effective Time.
Closing anticipated in the first quarter of 2027, subject to Proem shareholder approval and a minimum cash condition of $30 million; Proem Asset Management and affiliates committed $25 million of a roughly $50 million PIPE.
Churchill Downs closed an amendment to its senior secured credit agreement that extends its revolving credit facility and Term Loan A from 2029 to 2031. It also closed a new $500 million senior secured Term Loan B due 2033, which the company plans to use to repay existing term loan and revolver borrowings, fund fees, and for general corporate purposes. The filing does not report earnings or guidance, so its effect on shareholders depends on the terms of the new debt.
Revolver and Term Loan A maturities extended from 2029 to September 25, 2031
New $500 million Term Loan B due September 25, 2033, at SOFR plus 175 basis points, issued at 99.875% of principal
Net proceeds to repay term loan B-1 and revolving loans, pay fees and expenses, and for working capital
Company plans to fund redemption of its 5.50% Senior Notes due 2027 on October 19, 2026 from the revolver
Greenpro Capital Corp. completed the sale of six subsidiaries, collectively the F&A Entities, to Ms. Chen Yanhong on September 28, 2026, for cash consideration of HK$3,500,000, or about US$446,486. The filing says the F&A Entities are reported as discontinued operations and that the company estimates a $130,679 loss on the sale, so shareholders will see a smaller continuing business with a one-time loss.
Sale completed September 28, 2026, for HK$3,500,000 (about US$446,486) in cash to Ms. Chen Yanhong.
The buyer is a director of four of the sold entities and holds 14 shares of Greenpro common stock.
The company estimates a $130,679 loss on the sale and a $5,303,075 reduction in additional paid-in capital from waived intercompany balances.
Pro forma six-month 2026 revenue from continuing operations was $431,828, versus $707,553 historically; the F&A Entities principally provided corporate advisory and company-secretarial services.
RideNow Group entered a $220 million senior secured term loan with Centerbridge-affiliated lenders and Alter Domus, using proceeds to fully repay its 2021 Oaktree-agented credit agreement. The new loans mature in September 2031 but carry steep interest, and the company is in advanced talks for a $50 million ABL revolver with Wells Fargo that is not yet committed.
$220 million senior secured term loans due September 25, 2031, funded September 25, 2026 to refinance the Existing Credit Agreement with Oaktree
Interest at Base Rate plus 7.375% or Adjusted Term SOFR (3.00% floor) plus 8.375%
Financial covenants include a first-lien net leverage ratio up to 4.80 to 1.00 and minimum liquidity of $15 million
Three unsecured promissory notes totaling about $10.0 million, held by SH Capital Partners, Mark Tkach and Face Canyon, were amended with 13.0% PIK interest maturing August 31, 2028
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.